Impact Biomedicines
San Diego
About Impact Biomedicines
Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis and polycythemia vera.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $112.0M
- Funding stage: M&A
- Last round: Debt Financing (Oct 2017)
- Website: impactbiomedicines.com
- Phone: 858-221-0950
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/impact-biomedicines-93800 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.